Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Zydus Lifesciences (NSE: ZYDUSLIFE) wins NMPA approval for Desidustat in China, unlocking access to 120 million CKD patients Zydus Lifesciences' novel oral drug Desidustat receives China NMPA approval for CKD anaemia, unlocking a market of 120 million patients. Read the strategic analysis. byVenkateshMarch 16, 2026